UNSPSC 51343820: Lamivudine/nevirapine/zidovudine

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.

UNSPSC 51343820 Lamivudine/nevirapine/zidovudine is a Commodity code that describes specific antiretroviral medications used to treat HIV infection. The recent state and local opportunities tagged under this code show little relevant procurement activity; the most recent solicitations do not align with antiretroviral pharmaceutical procurement. Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and drug deactivation systems—opioid-response medical supplies unrelated to HIV treatment pharmaceuticals. The City of Tucson Fire Department's RFP 260217 (posted June 24, 2026) seeks BLS/ALS pharmaceuticals and supplies for emergency medical services, which encompasses a broad range of emergency care medications but does not specifically target antiretroviral drugs. Pinellas County, Florida's ITQ for certified reference materials (posted April 23, 2026) seeks drug standards for forensic analysis, not clinical pharmaceuticals. Minnesota's MMCAP generic multi-source pharmaceuticals RFP (posted January 20, 2026, due March 26, 2026) targets OTC products and generics distributed through authorized wholesalers but does not identify antiretrovirals among solicited product categories.

State and local governments rarely procure specific branded or generic HIV medications under dedicated UNSPSC commodity codes; antiretroviral purchasing typically flows through Medicaid managed-care plans, health department disease-management contracts, or integrated pharmacy benefit programs rather than standalone commodity solicitations. The code shows minimal recent direct-procurement activity at the state and local level. Geographic activity is sparse and scattered (Florida, Arizona, Minnesota) with no jurisdictions showing repeat activity under this specific code. No state or local issuing body named in the recent opportunities block has solicited lamivudine/nevirapine/zidovudine as a standalone procurement line item. If pursuing antiretroviral supply contracts, redirect focus to health department disease-surveillance RFPs, Medicaid pharmacy-services RFQs, or integrated behavioral-health and substance-use-disorder treatment solicitations where HIV care components may be embedded, rather than monitoring this narrow commodity code.